| Literature DB >> 25393414 |
Christiane Montag1, Laura Haase1, Dorothea Seidel2, Martin Bayerl1, Jürgen Gallinat1, Uwe Herrmann3, Karin Dannecker3.
Abstract
UNLABELLED: This pilot study aimed to evaluate the feasibility of an assessor-blind, randomised controlled trial of psychodynamic art therapy for the treatment of patients with schizophrenia, and to generate preliminary data on the efficacy of this intervention during acute psychotic episodes. Fifty-eight inpatients with DSM-diagnoses of schizophrenia were randomised to either 12 twice-weekly sessions of psychodynamic group art therapy plus treatment as usual or to standard treatment alone. Primary outcome criteria were positive and negative psychotic and depressive symptoms as well as global assessment of functioning. Secondary outcomes were mentalising function, estimated with the Reading the mind in the eyes test and the Levels of emotional awareness scale, self-efficacy, locus of control, quality of life and satisfaction with care. Assessments were made at baseline, at post-treatment and at 12 weeks' follow-up. At 12 weeks, 55% of patients randomised to art therapy, and 66% of patients receiving treatment as usual were examined. In the per-protocol sample, art therapy was associated with a significantly greater mean reduction of positive symptoms and improved psychosocial functioning at post-treatment and follow-up, and with a greater mean reduction of negative symptoms at follow-up compared to standard treatment. The significant reduction of positive symptoms at post-treatment was maintained in an attempted intention-to-treat analysis. There were no group differences regarding depressive symptoms. Of secondary outcome parameters, patients in the art therapy group showed a significant improvement in levels of emotional awareness, and particularly in their ability to reflect about others' emotional mental states. This is one of the first randomised controlled trials on psychodynamic group art therapy for patients with acute psychotic episodes receiving hospital treatment. Results prove the feasibility of trials on art therapy during acute psychotic episodes and justify further research to substantiate preliminary positive results regarding symptom reduction and the recovery of mentalising function. TRIAL REGISTRATION: ClinicalTrials.gov NCT01622166.Entities:
Mesh:
Year: 2014 PMID: 25393414 PMCID: PMC4231093 DOI: 10.1371/journal.pone.0112348
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1CONSORT 2010 flow diagram.
Baseline demographic and neuropsychological parameters, and illness characteristics in patients receiving art therapy or treatment as usual.
| Per-protocol sample | Intention-to-treat sample | |||||
| AT (n = 16) | TAU (n = 19) | Statistics | AT (n = 29) | TAU (n = 24) | Statistics | |
| Gender (m/f) | 7/9 | 15/4 |
| 19/10 | 19/5 | 1.206 |
| age (yrs) | 38.8±11.9 | 39.6±10.6 | 0.231 | 37.4±11.2 | 38.8±10.4 | 0.473 |
| education (yrs) | 15.3±4.6 | 13.2±4.1 | −1.438 | 14.2±4.6 | 13.7±4.0 | −0.460 |
| verbal IQ | 116.6±14.5 | 105.5±13.5 |
| 107.2±17.7 | 108.6±14.5 | 0.314 |
| AVLT (1–5) | 8.0±3.2 | 6.3±2.7 | −1.655 | 7.4±3.0 | 6.6±2.9 | −0.934 |
| AVLT (int) | 3.3±2.7 | 3.6±2.6 | 0.428 | 3.0±2.4 | 3.6±2.4 | 0.940 |
| duration of illness (yrs) | 12.1±12.1 | 15.2±9.3 | 0.839 | 11.3±10.8 | 13.9±9.2 | 0.932 |
| age of onset (yrs) | 26.6±9.2 | 24.5±8.7 | −0.713 | 25.6±7.6 | 24.4±8.8 | −0.497 |
| CPZ equiv. [mg] | 352.5±264.1 | 522.0±298.4 | 1.763 | 451.0±362.7 | 501.8±326.2 | 0.531 |
T-test for independent samples;
: χ2-test;
*: p<005 (AT: art therapy; TAU: treatment as usual; AVLT: Auditory verbal learning test; CPZ equiv.: antipsychotic dose converted to chlorpromazine equivalents).
Means, standard deviations, and group comparisons between art therapy and treatment as usual for psychopathological symptoms (SAPS, SANS, CDSS) and global assessment of functioning (GAF) in per-protocol and intention-to-treat samples at post-treatment and follow-up visits.
| baseline (0 wks) | post-treatment (6 wks) | follow-up (12 wks) | post-treatment (6 wks) | η | follow-up (12 wks) | η | ||||
| AT | TAU | AT | TAU | AT | TAU | AT vs.TAU | AT vs.TAU | |||
|
|
|
|
|
|
|
|
|
| ||
| SAPS | 60.0±26.2 | 55.3±26.7 | 19.1±19.8 | 37.1±23.1 | 13.3±16.4 | 35.0±30.9 |
|
|
|
|
| SANS | 48.9±20.6 | 38.1±19.2 | 24.1±15.6 | 27.9±16.2 | 15.9±13.8 | 30.8±18.1 | F[1; 32] = 1.441 | 0.043 |
|
|
| CDSS | 7.9±5.4 | 7.4±4.7 | 5.6±4.2 | 5.9±4.5 | 4.7±4.7 | 5.1±3.9 | F[1; 32] = 1.425 | 0.043 | F[1; 30] = 0.372 | 0.012 |
| GAF | 38.2±13.3 | 37.8±12.1 | 59.6±16.8 | 47.3±14.1 | 62.0±15.2 | 51.3±13.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| SAPS | 65.0±26.8 | 55.3±24.9 | 27.2±23.5 | 36.7±22.2 | 23.2±24.5 | 34.1±28.6 |
| - | F[1; 37.349] = 2.858 | - |
| SANS | 53.9±22.0 | 37.3±17.4 | 27.6±16.8 | 27.1±15.5 | 24.6±19.1 | 29.3±17.4 | F[1; 39.205] = 0.768 | - |
| - |
| CDSS | 7.4±5.5 | 6.7±4.5 | 6.4±4.5 | 5.9±3.9 | 5.3±4.5 | 5.3±3.9 | F[1; 33.011] = 0.024 | - | F[1; 30.793] = 0.031 | - |
| GAF | 37.0±12.8 | 38.4±11.0 | 52.4±17.2 | 48.0±14.0 | 55.8±17.8 | 51.2±14.4 | F[1; 38.297] = 1.114 | - | F[1; 35.663] = 1.036 | - |
: nAT = 16/nTAU = 19;
: nAT = 16/nTAU = 20;
: nAT = 24/nTAU = 29.
Per-protocol sample: ANCOVA factors: intervention, gender; covariates: verbal IQ, baseline value of dependent variable; F[df]; *: p<0.05; **: p<0.01; η2 p; corrected p-value (Bonferroni) p<0.0125 (significant results underlined).
Intention-to treat sample: descriptive statistics and ANCOVA on multiply imputed data (m = 50): covariates: intervention, baseline value of dependent variable; pooled F[df]; *: p<0.05; †: p = 0.078 (AT: art therapy; TAU: treatment as usual; SANS: Scale for the assessment of negative symptoms; SAPS: Scale for the assessment of positive symptoms; CDSS: Calgary depression scale for schizophrenia; GAF: Global assessment of functioning).
Means, standard deviations, group differences (F[df]) and effect sizes (η2 p) between art therapy and treatment as usual for social cognition (LEAS, RME), self-efficacy/locus of control (FKK), quality of life (MSQoL) and satisfaction with care (ZUF-8) scores in the per-protocol sample.
| baseline (0 weeks) | post-treatment (6 weeks) | follow-up 12 weeks) | post-treatment (6 weeks) | follow-up (12 weeks) | ||||
| AT | TAU | AT | TAU | AT | TAU | AT vs. TAU | AT vs. TAU | |
|
|
|
|
|
|
|
|
|
|
| LEAS-self | 23.6±6.5 | 22.2±8.0 | 29.3±5.4 | 24.8±6.5 | - | F[1;29] = 2,129 | - | |
| LEAS-other | 18.9±6.8 | 19.4±9.2 | 26.9±6.5 | 20.6±7.9 | - |
| - | |
| RME | 20.5±5.5 | 20.6±5.9 | 22.3±4.3 | 20.7±5.5 | - | F[1;30] = 0.653 | - | |
| FKK SKI | 60.5±15.1 | 68.3±12.9 | 56.4±9.3 | 64.6±10.0 | 58.9±10.7 | 67.93±10.3 | F[1;30] = 1.646 | F[1;28] = 0.561 |
| FKK PC | 62.4±18.2 | 60.7±13.5 | 55.6±13.0 | 54.4±16.5 | 52.4±10.8 | 57.5±13.2 | F[1;30] = 0.782 | F[1;28] = 3.989 |
| MSQoL | 183.9±40.8 | 194.7±46.8 | 202.6±42.2 | 218,3±33.3 | 224.1±36.4 | 214.3±34.7 | F[1;31] = 0.098 | F[1;29] = 3.251 |
| ZUF-8 | - | 16.7±4.5 | 14.1±4.4 | - | F[1;31] = 1.522 | - | ||
: nAT = 16/nTAU = 20;
: nAT = 16/nTAU = 19;
: ANCOVA factors: intervention, gender; covariates: verbal IQ, AVLT(1–5), baseline value of dependent variable.
: ANCOVA factors: intervention, gender; covariates: verbal IQ, baseline value of dependent variable; (post hoc) F[df]; *: p<0.05; corrected p-value (Bonferroni) p<0.007.
(LEAS: Levels of Emotional Awareness Scale; RME: Reading the Mind in the Eyes Test; FKK SKI: sum score self-efficacy; FKK PC: sum score externality; MSQoL: Modular system for quality of life; ZUF-8: satisfaction with care).